Clinical Trial Update: Niraparib Plus Anlotinib for Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating niraparib plus anlotinib for recurrent ovarian cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Niraparib (Niraparib)

Snippet

Sponsor: Lei Li | Conditions: Ovarian Carcinoma, Survival Outcomes | Phase 2 | Status: UNKNOWN